Although hepatitis C virus (HCV) infection is more common among adults with type 2 diabetes, it is uncertain whether HCV precedes the development of diabetes. Thus, we performed a prospective (case-cohort) analysis to examine if persons who acquired type 2 diabetes were more likely to have had antecedent HCV infection when enrolled in a community-based cohort of men and women between the ages of 44 and 65 in the United States (Atherosclerosis Risk in Communities Study [ARIC]). Among 1,084 adults free of diabetes at baseline, 548 developed diabetes over 9 years of follow-up evaluation. Incident cases of diabetes were identified by using fasting glucose and medical history and HCV antibodies were assessed at baseline. A priori, persons were categorized as low-risk or high-risk for diabetes based on their age and body mass index, factors that appeared to modify the type 2 diabetes-HCV infection incidence estimates. The overall prevalence of HCV in this population was 0.8%. Among those at high risk for diabetes, persons with HCV infection were more than 11 times as likely as those without HCV infection to develop diabetes (relative hazard, 11.58; 95% confidence interval, 1.39-96.6). Among those at low risk, no increased incidence of diabetes was detected among HCV-infected persons (relative hazard, 0.48; 95% confidence interval, 0.05-4.40). In conclusion, pre-existing HCV infection may increase the risk for type 2 diabetes in persons with recognized diabetes risk factors. Additional larger prospective evaluations are needed to confirm these preliminary findings.
Bibliographical noteFunding Information:
Abbreviations: HCV, hepatitis C virus; ARIC, Atherosclerosis Risk in Communities; BMI, body mass index; IQR, interquartile range. From the Departments of 1Epidemiology and 2Medicine, Johns Hopkins University, Baltimore, MD; and the 3Division of Epidemiology, University of Minnesota School of Public Health, Minneapolis, MN. Received November 8, 2002; accepted April 20, 2003. Supported in part by Public Health Service Grants, National Institutes of Health, National Institute on Drug Abuse: R01 DA10627 and F31 DA06007, and National Heart, Lung and Blood Institute, N01 HC55020. Address reprint requests to: Shruti H. Mehta, Ph.D., M.P.H., Assistant Research Professor, 615 N Wolfe St., E6012, Baltimore, MD 21205. E-mail: shmehta@ jhsph.edu; fax: 410-955-1383. Copyright © 2003 by the American Association for the Study of Liver Diseases. 0270-9139/03/3801-0009$30.00/0 doi:10.1053/jhep.2003.50291